News center
Product releases, technical notes, partnerships and company announcements from the FuBio team.
-
Supporting in vivo CAR-T development with engineered viral vectors
FuBio maintains a broad envelope and antibody library portfolio for in vivo CAR-T programs, in which CAR-encoding payloads are delivered directly to endogenous T cells.
-
CDE guidance classifies in vivo CAR-T as gene therapy
New Chinese guidance on the scope and classification of cell and gene therapy products places in vivo CAR-T within gene therapy, clarifying the pathway for developers.
-
Ebola pseudovirus quality control material available from stock
FuBio has released a pseudovirus quality control material for Ebola virus, intended for internal laboratory quality monitoring and diagnostic kit performance verification.
-
FuBio and Saifu Pharmaceutical announce a strategic partnership
The two companies combine viral vector engineering with preclinical evaluation and regulatory services to offer CGT developers an integrated development platform.
-
FuBio and Yuanxing Gene partner on vector engineering and CDMO
A strategic agreement links FuBio vector engineering platform with GMP-scale viral vector and mRNA CDMO capacity for CGT developers and clinical research hospitals.